Table 4 Laboratory findings Post-rituximab Administration in rFSGS.

From: Management and long-term outcome of recurrent idiopathic FSGS in pediatric kidney transplant recipients

Patient Number

IGG levels post rituximab (mg/dl)

CD19 post rituximab (%)

CD20 post rituximab

(%)

4

165

Data unavailable*

Data unavailable*

5

625

Data unavailable*

Data unavailable*

6

Data unavailable*

0 (after 2 doses)

0 (after 2 doses)

7

298

0.3

0

8

149

0

0

  1. The post-Rituximab period is defined as tests conducted within one month of administration.
  2. The clinical course of patient 5 (A) and 6 (B), who experienced rFSGS is depicted. The Y-axis represents the urine protein-to-creatinine ratio (uP/Cr) in mg/g, while the X-axis represents the time from transplantation (tx) in months (m).
  3. Preemptive PP - Preemptive plasmapheresis; Cont. PP - Continued PP post transplantation; LDL apheresis - Low-density lipoprotein apheresis.
Back to article page